Blinklab (BB1: $0.28) has added some additional image & vocal assessments into its autism diagnostic.
The company listed in April this year. In a previous study in 280 children, its smartphone-based test showed a very good sensitivity of 84% and specificity of 85%.
The addition of the extra measures, including head movements and vocal responses, has achieved an increase in sensitivity to 91% with specificity remaining similar, at 85%. The latest study, which commenced in 2023 in Morocco and the US, included 441 children.
Blinklab intends to start its US pivotal study, in approximately 500 children, by year's end. That study is expected to take around 12 months to complete, with an FDA submission for approval shortly thereafter, and a decision from the regulator expected possibly in mid 2026 if all goes well.
Blinklab is capitalized at $27 million with $5.4 million in cash at the end of September.
Bioshares recommendation: Speculative Buy Class B
Disclaimer:
Information contained in this newsletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates herein expressed represent the current judgement of the publisher and are subject to change. Blake Industry and Market Analysis Pty Ltd (BIMA) and any of their associates, officers or staff may have interests in securities referred to herein (Corporations Law s.849). Details contained herein have been prepared for general circulation and do not have regard to any person’s or company’s investment objectives, financial situation and particular needs. Accordingly, no recipients should rely on any recommendation (whether express or implied) contained in this document without consulting their investment adviser (Corporations Law s.851). The persons involved in or responsible for the preparation and publication of this report believe the information herein is accurate but no warranty of accuracy is given and persons seeking to rely on information provided herein should make their own independent enquiries. Details contained herein have been issued on the basis they are only for the particular person or company to whom they have been provided by Blake Industry and Market Analysis Pty Ltd. The Directors and/or associates declare interests in the following ASX Healthcare and Biotechnology sector securities: Analyst MP: 1AD, ACR, AVR, CGS, CUV, CYC, DXB, IMM, LBT, MX1, OPT, NEU, PAB, PXS,RNO,SOM. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than $100 are not disclosed.
